# Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

> **NCT02015663** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Tobramycin Inhalation Powder

## Key facts

- **NCT ID:** NCT02015663
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02015663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02015663, "Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02015663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*